恶性肿瘤患者血清β_2-MG检测的临床分析  

Clinical Significance of Detection of β_2-microglobulinin Patients with Malignant Tumor

作　　者：吴宗勇[1] 齐军[1] 贾德强[1] 张振杰[1] 穆建军[1] 

机构地区：[1]中国医学科学院肿瘤医院检验科,北京100021

出　　处：《标记免疫分析与临床》2010年第1期5-7,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：探讨血清β2-MG定量检测对恶性肿瘤的诊断价值。用免疫透射比浊法检测1800例恶性肿瘤患者、120例良性肿瘤患者和100名正常人(对照组)血清β2-MG水平。结果表明,各恶性肿瘤组与对照组血清β2-MG相比,差异均有统计学意义(P<0.05);良性肿瘤组与对照组血清β2-MG相比,差异无统计学意义(P>0.05)。乳腺癌组与良性肿瘤组的血清β2-MG相比,差异无统计学意义(P>0.05);肾癌、前列腺癌、膀胱癌、卵巢癌等恶性肿瘤组与良性肿瘤组的血清β2-MG相比,差异均有统计学意义(P<0.05)。除乳腺癌外,血清β2-MG有助于鉴别肾、前列腺、膀胱和卵巢等良恶性肿瘤。To explore the clinical value of detection of serum level of β2-MG in malignant tumor,the serum levels of β2-MG in 1800 patients with malignant tumor,120 patients with benign tumor and 100 healthy controls were measured by a transmission turbidmetic immunoassay.The results showed that the serum levels of β2-MG in patients with malignant tumor were significantly different with that of healthy controls（P〈0.05）,and there was no significant difference between patients with benign tumor and healthy controls（P〉0.05）.The serum β2-MG levels in patient with mammary cancer have no statistics significance compared with patients with benign tumor（P〉0.05）.The serum β2-MG levels in patients with kidney cancer,prostate cancer and ovarian cancer were significant different compared with patients with benign tumor（P〈0.05）.The serum β2-MG level may be helpful in identification of patients with benign or malignant tumor except mammary cancer.

关 键 词：恶性肿瘤 良性肿瘤 Β2-微球蛋白 免疫透射比浊法 

分 类 号：R730.4[医药卫生—肿瘤]